[
  {
    "row_id": "1",
    "regimen": "TQB2450 plus intensity-modulated radiotherapy",
    "drugs": [
      "TQB2450"
    ],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "1377P",
    "biomarkers": []
  },
  {
    "row_id": "2",
    "regimen": "neoadjuvant chemotherapy with docetaxel plus cisplatin and 5-fluorouracil",
    "drugs": [
      "docetaxel",
      "cisplatin",
      "5-fluorouracil"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "1362P",
    "biomarkers": []
  },
  {
    "row_id": "3",
    "regimen": "Paclitaxel, Cisplatin, and Capecitabine vs. Cisplatin and Fluorouracil as Induction Chemotherapy",
    "drugs": [
      "Paclitaxel",
      "Cisplatin",
      "Capecitabine",
      "Fluorouracil"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1370P",
    "biomarkers": []
  },
  {
    "row_id": "4",
    "regimen": "Anti-Angiogenic Drugs Reverse Immune Resistance",
    "drugs": [
      "Anti-Angiogenic Drugs"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1356P",
    "biomarkers": []
  },
  {
    "row_id": "5",
    "regimen": "the role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy",
    "drugs": [
      "systemic therapy"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1455eP",
    "biomarkers": []
  },
  {
    "row_id": "6",
    "regimen": "PD-L1+ Tumoral Extracellular Vesicles as Biomarkers of Immune-Related Toxicities",
    "drugs": [],
    "biomarkers": [
      "PD-L1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "318P"
  },
  {
    "row_id": "7",
    "regimen": "luvometinib (FCN-159) in recurrent or progressive pediatric low-grade glioma",
    "drugs": [
      "luvometinib (FCN-159)"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "661MO",
    "biomarkers": []
  },
  {
    "row_id": "8",
    "regimen": "Enhancing the Identification of Peri-Tumoral Regions in High-Grade Gliomas",
    "drugs": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "691P",
    "biomarkers": []
  },
  {
    "row_id": "9",
    "regimen": "DDX5 super-enhancer promote vasculogenic mimicry formation and metastasis",
    "drugs": [],
    "biomarkers": [
      "DDX5"
    ],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1432P"
  },
  {
    "row_id": "10",
    "regimen": "Survival Benefit of Curative Therapy in Functionally Frail Head and Neck Cancer Patients",
    "drugs": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1449eP",
    "biomarkers": []
  },
  {
    "row_id": "11",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "",
    "line": "",
    "phase": "",
    "trial_id": "ROW_4634"
  },
  {
    "row_id": "12",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "",
    "line": "",
    "phase": "",
    "trial_id": "ROW_4645"
  },
  {
    "row_id": "13",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "",
    "line": "",
    "phase": "",
    "trial_id": "ROW_4650"
  },
  {
    "row_id": "14",
    "regimen": "",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "",
    "line": "",
    "phase": "",
    "trial_id": "ROW_4665"
  },
  {
    "row_id": "15",
    "regimen": "Mechanisms and therapeutic interventions of KAT5-mediated immunotherapy resistance",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "11P"
  },
  {
    "row_id": "ROW_102",
    "regimen": "patient-derived tumour organoids for guiding treatment decisions",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1518MO",
    "regimen": "plasma exchange in melanoma",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "3071MO",
    "regimen": "Disitamab Vedotin plus Tislelizumab as Nephron-Sparing Therapy",
    "drugs": [
      "Disitamab Vedotin",
      "Tislelizumab",
      "disitamab vedotin",
      "tislelizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "DISTINCT-I"
  },
  {
    "row_id": "2385MO",
    "regimen": "T-cell phenotypes and clinical efficacy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2596MO",
    "regimen": "Ipilimumab, Nivolumab, and Ciforadenant",
    "drugs": [
      "Ipilimumab",
      "Nivolumab",
      "Ciforadenant",
      "nivolumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1b/2",
    "trial_id": ""
  },
  {
    "row_id": "1521MO",
    "regimen": "solnerstotug combined with cemiplimab",
    "drugs": [
      "solnerstotug",
      "cemiplimab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "LBA92",
    "regimen": "Docetaxel in Combination with Darolutamide + ADT",
    "drugs": [
      "Docetaxel",
      "Darolutamide"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "ARASAFE"
  },
  {
    "row_id": "926MO",
    "regimen": "MK-1084 Monotherapy",
    "drugs": [
      "MK-1084"
    ],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "KANDLELIT-001"
  },
  {
    "row_id": "927MO",
    "regimen": "Single-agent divarasib",
    "drugs": [
      "divarasib"
    ],
    "biomarkers": [
      "KRAS"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "925MO",
    "regimen": "oral Werner helicase inhibitor HRO761",
    "drugs": [
      "HRO761"
    ],
    "biomarkers": [
      "MSI",
      "dMMR"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1/Ib",
    "trial_id": ""
  },
  {
    "row_id": "1517MO",
    "regimen": "botensilimab and balstilimab",
    "drugs": [
      "botensilimab",
      "balstilimab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1b",
    "trial_id": ""
  },
  {
    "row_id": "3069MO",
    "regimen": "durvalumab plus neoadjuvant chemotherapy",
    "drugs": [
      "durvalumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "MIBC",
    "line": "Perioperative",
    "phase": "Not specified",
    "trial_id": "NIAGARA"
  },
  {
    "row_id": "1516MO",
    "regimen": "personalized cancer vaccine EVX-01",
    "drugs": [
      "EVX-01"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "LBA111",
    "regimen": "upfront Magnetic Resonance Imaging Versus Transurethral Resection",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "BladderPath"
  },
  {
    "row_id": "923MO",
    "regimen": "next generation, CNS-penetrant, PARP1-selective inhibitor SNV1521",
    "drugs": [
      "SNV1521"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "16",
    "regimen": "Exploration of Post-Treatment Strategies",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1347P"
  },
  {
    "row_id": "17",
    "regimen": "Update on the phase II study",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "661MO"
  },
  {
    "row_id": "18",
    "regimen": "Development of an Interpretable Machine Learning-Based Prediction Model",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1402P"
  },
  {
    "row_id": "19",
    "regimen": "DNA methylation-based epigenetic signatures",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "665MO"
  },
  {
    "row_id": "20",
    "regimen": "Enhancing the Identification of Peri-Tumoral Regions",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "691P"
  },
  {
    "row_id": "LBA58",
    "regimen": "pembrolizumab plus lenvatinib",
    "drugs": [
      "pembrolizumab",
      "lenvatinib"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "PLUME"
  },
  {
    "row_id": "1318O",
    "regimen": "Nimotuzumab Plus Cisplatin-Based Chemoradiotherapy",
    "drugs": [
      "Nimotuzumab",
      "Cisplatin",
      "cisplatin"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 3",
    "trial_id": "1318O"
  },
  {
    "row_id": "LBA103",
    "regimen": "Oral Nutritional Supplements During Concurrent Chemoradiotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "LBA103"
  },
  {
    "row_id": "2762MO",
    "regimen": "lurbinectedin + atezolizumab",
    "drugs": [
      "lurbinectedin",
      "atezolizumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "IMforte"
  },
  {
    "row_id": "1609MO",
    "regimen": "adjuvant nivolumab vs ipilimumab",
    "drugs": [
      "nivolumab",
      "ipilimumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 3",
    "trial_id": "CheckMate 238"
  },
  {
    "row_id": "1605MO",
    "regimen": "BNT111 in combination with cemiplimab",
    "drugs": [
      "BNT111",
      "cemiplimab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Phase 2",
    "trial_id": "Not specified"
  },
  {
    "row_id": "LBA52",
    "regimen": "Nofazinlimab combined with lenvatinib",
    "drugs": [
      "Nofazinlimab",
      "lenvatinib"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "LBA52"
  },
  {
    "row_id": "114MO",
    "regimen": "genomic-guided targeted therapies",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "IMPRESS-Norway"
  },
  {
    "row_id": "116MO",
    "regimen": "taselisib",
    "drugs": [
      "taselisib"
    ],
    "biomarkers": [
      "PIK3CA"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Phase 2",
    "trial_id": "LORELEI"
  },
  {
    "row_id": "2804MO",
    "regimen": "Cancer-associated cachexia indicators",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "2807MO",
    "regimen": "Predicting Chemotherapy-Related severe Hematological Toxicities",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "117MO",
    "regimen": "neoadjuvant anti-PD1",
    "drugs": [],
    "biomarkers": [
      "PD1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "1298eP",
    "regimen": "PD-1/CD20 Dual-Target Therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "LBA60",
    "regimen": "intralesional L19IL2/L19TNF",
    "drugs": [
      "L19IL2",
      "L19TNF"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "LBA60"
  },
  {
    "row_id": "ROW_994",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "ROW_994"
  },
  {
    "row_id": "ROW_790",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "ROW_790"
  },
  {
    "row_id": "ROW_774",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "ROW_774"
  },
  {
    "row_id": "ROW_796",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "ROW_796"
  },
  {
    "row_id": "ROW_1042",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "ROW_1042"
  },
  {
    "row_id": "1319O",
    "regimen": "perioperative camrelizumab plus chemotherapy",
    "drugs": [
      "camrelizumab",
      "chemotherapy"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Perioperative",
    "phase": "Phase 2",
    "trial_id": "CAMORAL"
  },
  {
    "row_id": "ROW_1286",
    "regimen": "recent data in resectable LA HNSCC",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1310",
    "regimen": "integrating novel strategies into patient care in resectable LA HNSCC",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1465",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1437",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1248",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1293",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1343",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1695",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1707",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1057P",
    "regimen": "epidemiological pattern in testicular cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2805MO",
    "regimen": "impact of Mediterranean dietary intervention",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1471MO",
    "regimen": "adding ipilimumab to atezolizumab plus bevacizumab",
    "drugs": [
      "Ipilimumab",
      "Atezolizumab",
      "Bevacizumab",
      "atezolizumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "PROD"
  },
  {
    "row_id": "2806MO",
    "regimen": "effect of a multidisciplinary intervention on fatigue",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "113MO",
    "regimen": "multimodal molecular investigation of rare cancer patients",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2781P",
    "regimen": "prognostic and predictive value of CD8 intratumoral density",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2679eP",
    "regimen": "CT-based intratumoral vascular feature",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1018eTiP",
    "regimen": "Phase I trial of RGT-61159",
    "drugs": [
      "RGT-61159"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "LBA35",
    "regimen": "EGFRÃ—HER3 Bispecific Antibody-drug Conjugate vs Physician's Choice of Chemotherapy",
    "drugs": [
      "Iza-Bren",
      "Chemotherapy"
    ],
    "biomarkers": [],
    "modality": [
      "Bispecific",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "BL-B01D1"
  },
  {
    "row_id": "LBA45",
    "regimen": "Relacorilant + Nab-paclitaxel",
    "drugs": [
      "Relacorilant",
      "Nab-paclitaxel"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "GOG3073"
  },
  {
    "row_id": "1464eP",
    "regimen": "genetic heterogeneity analysis",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_3210",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1450eP",
    "regimen": "locoregional recurrence analysis",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1418P",
    "regimen": "Fusobacterium nucleatum impact",
    "drugs": [],
    "biomarkers": [
      "Fusobacterium nucleatum",
      "Porphyromonas gingivalis"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "147P",
    "regimen": "gene expression panel for recurrence",
    "drugs": [],
    "biomarkers": [
      "Circulating Tumor Cells"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "LBA76",
    "regimen": "Paclitaxel-bevacizumab +/- atezolizumab",
    "drugs": [
      "Paclitaxel",
      "bevacizumab",
      "atezolizumab"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "IFCT-2201 ADAPTABLE"
  },
  {
    "row_id": "ROW_3256",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1438P",
    "regimen": "mortality trends analysis",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1421P",
    "regimen": "cisplatin and radiotherapy",
    "drugs": [
      "cisplatin"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1436P",
    "regimen": "nutrition impact on kidney disease",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_3278",
    "regimen": "invited discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1446eP",
    "regimen": "multidisciplinary care survey",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1372P",
    "regimen": "Nab-Paclitaxel combined with cisplatin and PD-1 inhibitor",
    "drugs": [
      "Nab-Paclitaxel",
      "cisplatin"
    ],
    "biomarkers": [
      "PD-1"
    ],
    "modality": [
      "Chemotherapy",
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": ""
  },
  {
    "row_id": "1426P",
    "regimen": "real-world use of pembrolizumab",
    "drugs": [
      "pembrolizumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "HNSCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1463eP",
    "regimen": "gas metabolite patterns analysis",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1373P",
    "regimen": "Tislelizumab combined with TP Regimen",
    "drugs": [
      "Tislelizumab",
      "tislelizumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": ""
  },
  {
    "row_id": "1387P",
    "regimen": "tumor heterogeneity analysis",
    "drugs": [],
    "biomarkers": [
      "EBV-DNA"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1371P",
    "regimen": "Nivolumab plus chemoradiotherapy",
    "drugs": [
      "Nivolumab",
      "nivolumab",
      "cisplatin"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "NPC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1444eP",
    "regimen": "lymph nodes and extranodal extension impact",
    "drugs": [],
    "biomarkers": [
      "HPV-positive"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1403P",
    "regimen": "transcriptomic signatures validation",
    "drugs": [
      "nivolumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "HNSCC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1338P",
    "regimen": "neoadjuvant PARP inhibitor and immunotherapy",
    "drugs": [
      "PARP inhibitor",
      "immunotherapy"
    ],
    "biomarkers": [
      "HPV-negative"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "PRIME H&N Study"
  },
  {
    "row_id": "1346P",
    "regimen": "sequential immune checkpoint inhibitor and cetuximab-based chemotherapy",
    "drugs": [
      "immune checkpoint inhibitor",
      "cetuximab",
      "chemotherapy"
    ],
    "biomarkers": [],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Pooled Analysis"
  },
  {
    "row_id": "1351P",
    "regimen": "low-dose weekly carboplatin and paclitaxel metronomic chemotherapy",
    "drugs": [
      "carboplatin",
      "paclitaxel"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "Not specified"
  },
  {
    "row_id": "1345P",
    "regimen": "omission of elective neck irradiation",
    "drugs": [],
    "biomarkers": [
      "pT3-T4 Oral Squamous Cell Carcinoma",
      "pN0 Neck"
    ],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "1359P",
    "regimen": "1st line treatment in recurrent/metastatic head and neck squamous cell carcinoma",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "REALKEY"
  },
  {
    "row_id": "1374P",
    "regimen": "exploratory analysis of microenvironment-informed delta radiomics",
    "drugs": [
      "pembrolizumab",
      "gemcitabine",
      "cisplatin"
    ],
    "biomarkers": [],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "NEOSPACE"
  },
  {
    "row_id": "1428P",
    "regimen": "anti-PD-1 immune checkpoint inhibitors combined with cetuximab",
    "drugs": [
      "anti-PD-1",
      "cetuximab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "1353P",
    "regimen": "discontinuing immune checkpoint inhibitors",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "1405P",
    "regimen": "AI informed virtual immunocyte profiling",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "VIPER"
  },
  {
    "row_id": "80MO",
    "regimen": "durvalumab plus tremelimumab",
    "drugs": [
      "durvalumab",
      "tremelimumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "IMMUNOBIL GER"
  },
  {
    "row_id": "1659P",
    "regimen": "neoadjuvant immunotherapy",
    "drugs": [
      "cetuximab"
    ],
    "biomarkers": [
      "PD-L1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "NRG-HN014"
  },
  {
    "row_id": "1415P",
    "regimen": "PD-L1 expression analysis",
    "drugs": [],
    "biomarkers": [
      "PD-L1",
      "TIGIT",
      "CD155"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1352P",
    "regimen": "Amivantamab plus paclitaxel",
    "drugs": [
      "Amivantamab",
      "paclitaxel"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1341P",
    "regimen": "follow-up strategy assessment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "HETECO"
  },
  {
    "row_id": "128P",
    "regimen": "anti-PD(L)1 immunotherapy",
    "drugs": [],
    "biomarkers": [
      "PTI Score"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1701eTiP",
    "regimen": "neoadjuvant immunotherapy with response-adapted treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 3",
    "trial_id": "NRG-HN014"
  },
  {
    "row_id": "LBA27",
    "regimen": "SM-1 combined with temozolomide",
    "drugs": [
      "SM-1",
      "temozolomide"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "LBA51",
    "regimen": "Atezolizumab plus Bevacizumab",
    "drugs": [
      "Atezolizumab",
      "Bevacizumab",
      "atezolizumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "",
    "phase": "Phase IIIb",
    "trial_id": "IKF-035/ABC-HCC"
  },
  {
    "row_id": "555MO",
    "regimen": "Datopotamab deruxtecan plus durvalumab",
    "drugs": [
      "Datopotamab deruxtecan",
      "durvalumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "487MO",
    "regimen": "CDK4/6 inhibitors",
    "drugs": [],
    "biomarkers": [
      "HER2"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "720eP",
    "regimen": "Therapeutic Drug Monitoring",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "81MO",
    "regimen": "Tinengotinib in advanced CCA",
    "drugs": [
      "Tinengotinib"
    ],
    "biomarkers": [
      "FGFR"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "LBA85",
    "regimen": "short-course versus long-course chemotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "",
    "phase": "Phase 3",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4035",
    "regimen": "consolidation and ablative therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4053",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_4120",
    "regimen": "Circulating EBV DNA for treatment selection",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1408P",
    "regimen": "C-FAST assessment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2280MO",
    "regimen": "Control Groups in Cancer Trials",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "213eP",
    "regimen": "Therapeutic Drug Monitoring",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "FORAGER-1",
    "regimen": "LY3866288 in FGFR3-altered advanced solid tumors",
    "drugs": [
      "LY3866288"
    ],
    "biomarkers": [
      "FGFR3"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "FORAGER-1"
  },
  {
    "row_id": "SAKK 01/10",
    "regimen": "Single-dose carboplatin and involved-node radiotherapy",
    "drugs": [
      "carboplatin"
    ],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "SAKK 01/10",
    "biomarkers": []
  },
  {
    "row_id": "SunRISe-4",
    "regimen": "Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab",
    "drugs": [
      "gemcitabine",
      "cetrelimab"
    ],
    "modality": [
      "Intravesical"
    ],
    "population": "MIBC",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "SunRISe-4",
    "biomarkers": []
  },
  {
    "row_id": "START-001",
    "regimen": "invikafusp alfa as monotherapy",
    "drugs": [
      "invikafusp alfa"
    ],
    "modality": [
      "Bispecific"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "START-001",
    "biomarkers": []
  },
  {
    "row_id": "METROPH",
    "regimen": "Metronomic Cyclophosphamide VS Doxorubicin",
    "drugs": [
      "Cyclophosphamide",
      "Doxorubicin"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "METROPH",
    "biomarkers": []
  },
  {
    "row_id": "COTESARC",
    "regimen": "Combination of MEK and PDL-1 inhibitors",
    "drugs": [
      "MEK",
      "PDL-1 inhibitors"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase I-II",
    "trial_id": "COTESARC",
    "biomarkers": []
  },
  {
    "row_id": "PETRANHA",
    "regimen": "saruparib + androgen receptor pathway inhibitors",
    "drugs": [
      "saruparib",
      "androgen receptor pathway inhibitors"
    ],
    "modality": [
      "TKI"
    ],
    "population": "mPC",
    "line": "1L",
    "phase": "Phase 1/2",
    "trial_id": "PETRANHA",
    "biomarkers": []
  },
  {
    "row_id": "AMPLITUDE",
    "regimen": "niraparib and abiraterone acetate plus prednisone",
    "drugs": [
      "niraparib",
      "abiraterone acetate",
      "prednisone"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "AMPLITUDE",
    "biomarkers": []
  },
  {
    "row_id": "1515MO",
    "regimen": "mRNA-4359 Plus Pembrolizumab",
    "drugs": [
      "mRNA-4359",
      "Pembrolizumab",
      "pembrolizumab"
    ],
    "biomarkers": [
      "PD-L1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1515MO"
  },
  {
    "row_id": "1520MO",
    "regimen": "anti-CD137 switch antibody agonist STA551 as monotherapy and in combination with atezolizumab",
    "drugs": [
      "STA551",
      "atezolizumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "1520MO",
    "biomarkers": []
  },
  {
    "row_id": "1519MO",
    "regimen": "systemic STING agonist BI 1703880 plus ezabenlimab",
    "drugs": [
      "BI 1703880",
      "ezabenlimab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase Ia",
    "trial_id": "1519MO",
    "biomarkers": []
  },
  {
    "row_id": "1522MO",
    "regimen": "INCA33890, A PD-1/TGFbetaR2 Bispecific Antibody",
    "drugs": [
      "INCA33890"
    ],
    "modality": [
      "Bispecific"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "1522MO",
    "biomarkers": []
  },
  {
    "row_id": "2802O",
    "regimen": "Home-based supervised physical activity for metastatic cancer patients receiving oral targeted therapy",
    "drugs": [
      "oral targeted therapy"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "2802O",
    "biomarkers": []
  },
  {
    "row_id": "2687MO",
    "regimen": "nivolumab+/-relatlimab",
    "drugs": [
      "nivolumab",
      "relatlimab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase II",
    "trial_id": "2687MO",
    "biomarkers": []
  },
  {
    "row_id": "2688MO",
    "regimen": "FOG-001, a first-in-class direct beta-catenin:TCF4 inhibitor",
    "drugs": [
      "FOG-001"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1/2",
    "trial_id": "2688MO",
    "biomarkers": []
  },
  {
    "row_id": "ROW_97",
    "regimen": "Invited Discussant",
    "trial_id": "ROW_97",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_126",
    "regimen": "Combinations of cell death modulators and other therapies",
    "trial_id": "ROW_126",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_128",
    "regimen": "Invited Discussant",
    "trial_id": "ROW_128",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_132",
    "regimen": "Invited Discussant",
    "trial_id": "ROW_132",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_137",
    "regimen": "The rationale behind drug combinations",
    "trial_id": "ROW_137",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_181",
    "regimen": "Invited Discussant",
    "trial_id": "ROW_181",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2420MO",
    "regimen": "Effects of prostate radiotherapy (RT) on synchronous, metastatic, hormone-sensitive prostate cancer (mHSPC)",
    "trial_id": "2420MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "LBA99",
    "regimen": "BIOmarker driven trial of Vegf2 inhibitor in Advanced or metastatic Sarcoma",
    "trial_id": "LBA99",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2691MO",
    "regimen": "Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib",
    "trial_id": "2691MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2605MO",
    "regimen": "Final efficacy data and biomarker analysis from the clear cell cohort of CALYPSO",
    "trial_id": "2605MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "3072MO",
    "regimen": "Datopotamab deruxtecan + rilvegostomig",
    "drugs": [
      "Datopotamab deruxtecan",
      "rilvegostomig"
    ],
    "population": "mUC",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "TROPION-PanTumor",
    "biomarkers": []
  },
  {
    "row_id": "924MO",
    "regimen": "ART6043 as monotherapy and in combination with olaparib",
    "drugs": [
      "ART6043",
      "olaparib"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2690MO",
    "regimen": "pimicotinib",
    "drugs": [
      "pimicotinib"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "MANEUVER",
    "biomarkers": []
  },
  {
    "row_id": "922MO",
    "regimen": "AMT-116",
    "drugs": [
      "AMT-116"
    ],
    "population": "Other",
    "phase": "Phase I/II",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2689MO",
    "regimen": "Chidamide and Toripalimab",
    "drugs": [
      "Chidamide",
      "Toripalimab",
      "toripalimab"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase II",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2592MO",
    "regimen": "Fruquintinib plus sintilimab versus axitinib or everolimus",
    "drugs": [
      "Fruquintinib",
      "sintilimab",
      "axitinib",
      "everolimus"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "3012MO",
    "regimen": "Metastasis dissemination and divergence timing",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "TRACERx"
  },
  {
    "row_id": "1320O",
    "regimen": "Postoperative adjuvant radiochemotherapy with cisplatin vs. aRCH plus pembrolizumab",
    "drugs": [
      "cisplatin",
      "pembrolizumab"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "ADRI"
  },
  {
    "row_id": "1229eP",
    "regimen": "Biparatopic FRalpha-Targeting ADC",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "GenSci140"
  },
  {
    "row_id": "3196eP",
    "regimen": "Determining Line of Therapy with LLMs",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "3196eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2808MO",
    "regimen": "Impact of Proton Pump Inhibitors on Immunotherapy Outcomes",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2808MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1603MO",
    "regimen": "Adjuvant cemiplimab vs placebo",
    "drugs": [
      "cemiplimab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 3",
    "trial_id": "C-POST",
    "biomarkers": []
  },
  {
    "row_id": "LBA59",
    "regimen": "Combined Percutaneous Hepatic Perfusion with Ipilimumab plus Nivolumab",
    "drugs": [
      "Ipilimumab",
      "Nivolumab",
      "nivolumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "CHOPIN",
    "biomarkers": []
  },
  {
    "row_id": "2543MO",
    "regimen": "Multimodal Digital Therapeutic for Cancer-Related Fatigue",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2543MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1MO",
    "regimen": "Placental features overexpression",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "CN157",
    "regimen": "Enhancing Adherence to Oral Hormone Therapy",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "CN157",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1317O",
    "regimen": "neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO)",
    "drugs": [
      "durvalumab"
    ],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 3",
    "trial_id": "CompARE",
    "biomarkers": []
  },
  {
    "row_id": "1348MO",
    "regimen": "tiragolumab (tira) + atezolizumab (atezo) and atezo + placebo (pbo) as first-line (1L) treatment",
    "drugs": [
      "tiragolumab",
      "atezolizumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "SKYSCRAPER-09",
    "biomarkers": [
      "PD-L1"
    ]
  },
  {
    "row_id": "CN90",
    "regimen": "chemoradiation",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "CN90"
  },
  {
    "row_id": "2209eP",
    "regimen": "intravenous (ivST) versus oral systemic treatment (oST)",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2209eP"
  },
  {
    "row_id": "2949eP",
    "regimen": "oral treatments",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2949eP"
  },
  {
    "row_id": "1065MO",
    "regimen": "AZD5335, a folate receptor alpha (FRalpha)-targeted antibody-drug conjugate",
    "drugs": [
      "AZD5335"
    ],
    "biomarkers": [
      "FRalpha"
    ],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "1065MO"
  },
  {
    "row_id": "LBA41",
    "regimen": "baseline multiplex cytokine profiling",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "LBA41"
  },
  {
    "row_id": "LBA43",
    "regimen": "TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate",
    "drugs": [
      "TUB-040"
    ],
    "biomarkers": [],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "LBA43"
  },
  {
    "row_id": "294MO",
    "regimen": "giredestrant or tamoxifen (tam)",
    "drugs": [
      "giredestrant",
      "tamoxifen"
    ],
    "biomarkers": [
      "HER2"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "294MO"
  },
  {
    "row_id": "2613MO",
    "regimen": "Nivolumab plus Ipilimumab Therapy",
    "drugs": [
      "Nivolumab",
      "Ipilimumab",
      "nivolumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "mUC",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "COSMIC 313"
  },
  {
    "row_id": "1323MO",
    "regimen": "Evorpacept in combination with Pembrolizumab",
    "drugs": [
      "Evorpacept",
      "Pembrolizumab",
      "pembrolizumab"
    ],
    "biomarkers": [
      "PD-L1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "ASPEN-03"
  },
  {
    "row_id": "LBA44",
    "regimen": "Durvalumab + Paclitaxel/Carboplatin + Bevacizumab followed by Durvalumab, Bevacizumab + Olaparib maintenance",
    "drugs": [
      "Durvalumab",
      "Paclitaxel",
      "Carboplatin",
      "Bevacizumab",
      "Olaparib",
      "durvalumab",
      "carboplatin"
    ],
    "biomarkers": [],
    "modality": [
      "ADC",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Maintenance",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1510TiP",
    "regimen": "Oral Fecal Microbiota Capsule for Reprogramming Immunity",
    "drugs": [
      "Oral Fecal Microbiota Capsule"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": ""
  },
  {
    "row_id": "1247MO",
    "regimen": "Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "889eP",
    "regimen": "adjuvant treatment in localized colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2189P",
    "regimen": "Active oncologic treatment in the last month of life",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1970",
    "regimen": "oral SERD in HR+, HER2- MBC",
    "drugs": [
      "oral SERD"
    ],
    "biomarkers": [
      "HR+",
      "HER2-",
      "HER2"
    ],
    "modality": [],
    "population": "MIBC",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2559P",
    "regimen": "cognitive behavioral therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_1994",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "ROW_2031",
    "regimen": "Invited Discussant",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "919O",
    "regimen": "oral IAG933 in advanced mesothelioma",
    "drugs": [
      "oral IAG933"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Phase 1",
    "trial_id": ""
  },
  {
    "row_id": "876eP",
    "regimen": "patterns in mode of presentation for colorectal cancer",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "732MO",
    "regimen": "ctDNA clearance in INTERCEPT colorectal cancer study",
    "drugs": [],
    "biomarkers": [
      "ctDNA"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1250MO",
    "regimen": "Second-Line Therapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2890P",
    "regimen": "Remote Monitoring of Patients Receiving Oral or Intravenous Anticancer Treatments",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1244MO",
    "regimen": "Response Assessment with Sequential Whole Body Magnetic Resonance Imaging",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "2849P",
    "regimen": "low-molecular-weight heparins vs direct oral anticoagulants",
    "drugs": [
      "low-molecular-weight heparins",
      "direct oral anticoagulants"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2849P",
    "biomarkers": []
  },
  {
    "row_id": "916O",
    "regimen": "INCB161734, A Novel Oral KRAS G12D Inhibitor",
    "drugs": [
      "INCB161734"
    ],
    "population": "Other",
    "phase": "Phase 1",
    "trial_id": "916O",
    "biomarkers": [
      "KRAS"
    ]
  },
  {
    "row_id": "727MO",
    "regimen": "FOLFOX plus PANITUMUMAB",
    "drugs": [
      "FOLFOX",
      "PANITUMUMAB"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "727MO",
    "biomarkers": []
  },
  {
    "row_id": "2921eP",
    "regimen": "medical oral nutrition supplement",
    "drugs": [
      "medical oral nutrition supplement"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "2921eP",
    "biomarkers": []
  },
  {
    "row_id": "LBA46",
    "regimen": "TAK228 in Combination With Intravenous Weekly Paclitaxel",
    "drugs": [
      "TAK228",
      "Intravenous Weekly Paclitaxel"
    ],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "LBA46",
    "biomarkers": []
  },
  {
    "row_id": "737MO",
    "regimen": "Trastuzumab deruxtecan (T-DXd)",
    "drugs": [
      "Trastuzumab deruxtecan"
    ],
    "biomarkers": [
      "HER2"
    ],
    "population": "mCRC",
    "phase": "Phase 2",
    "trial_id": "737MO"
  },
  {
    "row_id": "1324MO",
    "regimen": "evorpacept in combination with pembrolizumab and chemotherapy",
    "drugs": [
      "evorpacept",
      "pembrolizumab",
      "chemotherapy"
    ],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "1324MO",
    "biomarkers": []
  },
  {
    "row_id": "1327MO",
    "regimen": "Amivantamab in recurrent/metastatic head & neck squamous cell cancer after disease progression on checkpoint inhibition and chemotherapy",
    "drugs": [
      "Amivantamab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 1",
    "trial_id": "OrigAM",
    "biomarkers": []
  },
  {
    "row_id": "2951eP",
    "regimen": "Efficacy of Ketamine for Oral And Pharyngeal Mucositis Pain",
    "drugs": [
      "Ketamine"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "KARM",
    "biomarkers": []
  },
  {
    "row_id": "297MO",
    "regimen": "Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain",
    "drugs": [
      "Pegfilgrastim"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "979P",
    "regimen": "Phase 1 dose escalation study of T-1101 (Tosylate) Capsule",
    "drugs": [
      "T-1101 (Tosylate)"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2600MO",
    "regimen": "Comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer",
    "drugs": [
      "ipilimumab",
      "nivolumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "SUNNIFORECAST",
    "biomarkers": [
      "PD-L1"
    ]
  },
  {
    "row_id": "LBA40",
    "regimen": "WES-derived Aneuploidy score identifies MMRd patients with reduced benefit from immunotherapy",
    "drugs": [],
    "biomarkers": [
      "MMRd"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "AtTEnd/ENGOT-EN7"
  },
  {
    "row_id": "2599MO",
    "regimen": "Soluble MAdCAM-1 predicts outcomes in patients with metastatic renal cell carcinoma",
    "drugs": [],
    "biomarkers": [
      "MAdCAM-1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified"
  },
  {
    "row_id": "323MO",
    "regimen": "Efficacy of adjuvant anti-PD-L1 avelumab by tumor infiltrating lymphocytes for high-risk triple negative breast cancer",
    "drugs": [
      "avelumab"
    ],
    "biomarkers": [
      "PD-L1"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 3",
    "trial_id": "A-BRAVE"
  },
  {
    "row_id": "2595MO",
    "regimen": "Comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment",
    "drugs": [
      "Ipilimumab",
      "Nivolumab",
      "nivolumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "SUNNIFORECAST",
    "biomarkers": []
  },
  {
    "row_id": "1328MO",
    "regimen": "hypofractionated radiotherapy + pembrolizumab",
    "drugs": [
      "pembrolizumab"
    ],
    "modality": [
      "Radiotherapy",
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1328MO",
    "biomarkers": []
  },
  {
    "row_id": "1849MO",
    "regimen": "encorafenib + binimetinib",
    "drugs": [
      "encorafenib",
      "binimetinib"
    ],
    "population": "mUC",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "1849MO",
    "biomarkers": []
  },
  {
    "row_id": "731MO",
    "regimen": "telisotuzumab adizutecan + bevacizumab",
    "drugs": [
      "telisotuzumab adizutecan",
      "bevacizumab"
    ],
    "population": "Other",
    "line": "3L",
    "phase": "Not specified",
    "trial_id": "731MO",
    "biomarkers": []
  },
  {
    "row_id": "295MO",
    "regimen": "neoadjuvant chemotherapy",
    "drugs": [],
    "biomarkers": [
      "Ki-67"
    ],
    "modality": [
      "Chemotherapy",
      "Neoadjuvant"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "295MO"
  },
  {
    "row_id": "1249MO",
    "regimen": "Bexmarilimab + Azacitidine",
    "drugs": [
      "Bexmarilimab",
      "Azacitidine"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1/2",
    "trial_id": "1249MO",
    "biomarkers": []
  },
  {
    "row_id": "1329MO",
    "regimen": "enfortumab vedotin + pembrolizumab",
    "drugs": [
      "enfortumab vedotin",
      "pembrolizumab"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1329MO",
    "biomarkers": []
  },
  {
    "row_id": "293MO",
    "regimen": "neoadjuvant vepdegestrant or anastrozole",
    "drugs": [
      "vepdegestrant",
      "anastrozole"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "293MO",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "1846MO",
    "regimen": "olomorasib in patients with KRAS G12C-mutant NSCLC",
    "drugs": [
      "olomorasib"
    ],
    "biomarkers": [
      "KRAS G12C",
      "KRAS"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1846MO"
  },
  {
    "row_id": "2593MO",
    "regimen": "LAG3 expression patterns and immunotherapy response",
    "drugs": [],
    "biomarkers": [
      "LAG3"
    ],
    "modality": [
      "IO"
    ],
    "population": "mUC",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "2593MO"
  },
  {
    "row_id": "1325MO",
    "regimen": "Retifanlimab Alone Or In Combination With Anti-LAG3 +/- Anti-TIM3 mAbs",
    "drugs": [
      "Retifanlimab"
    ],
    "biomarkers": [
      "PD-L1",
      "LAG3",
      "TIM3"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1325MO"
  },
  {
    "row_id": "1016eTiP",
    "regimen": "LY4066434 in KRAS-mutant solid tumors",
    "drugs": [
      "LY4066434"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "1016eTiP",
    "biomarkers": [
      "KRAS"
    ]
  },
  {
    "row_id": "292MO",
    "regimen": "Durvalumab in Combination with Neoadjuvant Chemotherapy",
    "drugs": [
      "Durvalumab",
      "durvalumab"
    ],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "292MO",
    "biomarkers": []
  },
  {
    "row_id": "1246MO",
    "regimen": "R-CHOP and Anti-CD19 CAR T Therapies",
    "drugs": [
      "R-CHOP",
      "Anti-CD19 CAR T"
    ],
    "modality": [
      "Chemotherapy",
      "CAR-T"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1246MO",
    "biomarkers": []
  },
  {
    "row_id": "2828P",
    "regimen": "Pirfenidone in the Treatment of Radiation-Induced Oral Mucositis",
    "drugs": [
      "Pirfenidone"
    ],
    "modality": [
      "Other"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "2828P",
    "biomarkers": []
  },
  {
    "row_id": "730MO",
    "regimen": "Trifluridine/Tipiracil + Capecitabine + Bevacizumab",
    "drugs": [
      "Trifluridine",
      "Tipiracil",
      "Capecitabine",
      "Bevacizumab"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "TriComB",
    "biomarkers": []
  },
  {
    "row_id": "1566P",
    "regimen": "Intratumoral JNJ-87704916 + Cetrelimab",
    "drugs": [
      "JNJ-87704916",
      "Cetrelimab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "2594MO",
    "regimen": "KIM-1 levels association",
    "biomarkers": [
      "KIM-1"
    ],
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "COSMIC-313",
    "drugs": []
  },
  {
    "row_id": "2229P",
    "regimen": "Oxaliplatin + Irinotecan Liposome + 5-FU/LV",
    "drugs": [
      "Oxaliplatin",
      "Irinotecan Liposome",
      "5-FU",
      "LV"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "1248MO",
    "regimen": "Venetoclax-containing regimen",
    "drugs": [
      "Venetoclax"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "CN126",
    "regimen": "ondansetron oral soluble film-based regimens",
    "drugs": [
      "ondansetron"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "734MO",
    "regimen": "blood-based early cancer detection test",
    "modality": [
      "Not specified"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1330MO",
    "regimen": "neoadjuvant-adjuvant pembrolizumab + SOC",
    "drugs": [
      "pembrolizumab"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "LBA34",
    "regimen": "sirexatamab + bevacizumab + chemotherapy",
    "drugs": [
      "sirexatamab",
      "bevacizumab"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "DeFianCe Trial",
    "biomarkers": []
  },
  {
    "row_id": "1245MO",
    "regimen": "Mitoxantrone Hydrochloride Liposome + Chidamide",
    "drugs": [
      "Mitoxantrone Hydrochloride Liposome",
      "Chidamide"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "1388P",
    "regimen": "Incidence Patterns and Survival Trajectories",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1388P"
  },
  {
    "row_id": "1458eP",
    "regimen": "Biomarker and Genomic Landscape Study",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1458eP"
  },
  {
    "row_id": "1437P",
    "regimen": "Prediction of 1-Year Recurrence-Free Survival",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1437P"
  },
  {
    "row_id": "1337P",
    "regimen": "superselective intra-arterial cisplatin and concomitant radiotherapy",
    "drugs": [
      "cisplatin"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1337P"
  },
  {
    "row_id": "1419P",
    "regimen": "radiation therapy",
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1419P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1401P",
    "regimen": "APG-157-Induced Anti-Tumor Immune Remodeling",
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1401P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1390P",
    "regimen": "Becotatug Vedotin combined with Pucotenlimab",
    "drugs": [
      "Becotatug Vedotin",
      "Pucotenlimab"
    ],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "1390P",
    "biomarkers": []
  },
  {
    "row_id": "1461eP",
    "regimen": "miRNA Signatures as Diagnostic Biomarker",
    "biomarkers": [
      "miRNA"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1461eP",
    "drugs": []
  },
  {
    "row_id": "ROW_3399",
    "regimen": "Maintenance therapy after chemo-immunotherapy",
    "modality": [
      "Maintenance"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "ROW_3399",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "235eP",
    "regimen": "Chemotherapy Survival Status",
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "235eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "LBA106",
    "regimen": "Niraparib in relapsed mesothelioma",
    "drugs": [
      "Niraparib"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "LBA106",
    "biomarkers": []
  },
  {
    "row_id": "1424P",
    "regimen": "Comparative Diagnostic Performance of CBCT and CT",
    "modality": [
      "Other"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1424P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1465eTiP",
    "regimen": "Tislelizumab Combined with Chemotherapy Followed by Radiotherapy/Adaptive Surgery",
    "drugs": [
      "Tislelizumab",
      "tislelizumab"
    ],
    "modality": [
      "IO",
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1465eTiP",
    "biomarkers": []
  },
  {
    "row_id": "LBA26",
    "regimen": "LY4064809 (STX-478), a pan-mutant-selective PI3Kalpha inhibitor",
    "drugs": [
      "LY4064809",
      "STX-478"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "phase": "Phase 1",
    "trial_id": "LBA26",
    "biomarkers": []
  },
  {
    "row_id": "LBA48",
    "regimen": "buparlisib plus paclitaxel",
    "drugs": [
      "buparlisib",
      "paclitaxel"
    ],
    "biomarkers": [
      "PD-1",
      "PD-L1"
    ],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "BURAN"
  },
  {
    "row_id": "662MO",
    "regimen": "concomitant radiotherapy with olaparib and temozolomide",
    "drugs": [
      "olaparib",
      "temozolomide"
    ],
    "modality": [
      "Radiotherapy",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "OLA-TMZ-RTE-01",
    "biomarkers": []
  },
  {
    "row_id": "200eP",
    "regimen": "dual PD-L1 and TGFbeta inhibition",
    "drugs": [],
    "biomarkers": [
      "PD-L1",
      "TGFbeta"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1817MO",
    "regimen": "osimertinib",
    "drugs": [
      "osimertinib"
    ],
    "biomarkers": [
      "EGFR",
      "EGFRm"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "LAURA"
  },
  {
    "row_id": "1671P",
    "regimen": "cutaneous angiosarcoma treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1425P",
    "regimen": "locally advanced head and neck cancer treatment",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "486MO",
    "regimen": "camizestrant plus CDK4/6 inhibitor",
    "drugs": [
      "camizestrant",
      "CDK4/6 inhibitor"
    ],
    "biomarkers": [
      "ESR1m",
      "HER2"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "SERENA-6"
  },
  {
    "row_id": "1462eP",
    "regimen": "risk prediction involving KIF13B variant",
    "drugs": [],
    "biomarkers": [
      "KIF13B c.*3163G>A"
    ],
    "modality": [],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1392P",
    "regimen": "avelumab in high-risk oral potentially malignant disorders",
    "drugs": [
      "avelumab"
    ],
    "biomarkers": [],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "Impede"
  },
  {
    "row_id": "LBA25",
    "regimen": "Culmerciclib Plus Fulvestrant",
    "drugs": [
      "Culmerciclib",
      "Fulvestrant"
    ],
    "modality": [
      "TKI",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "CULMINATE-2",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "LBA22",
    "regimen": "sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab",
    "drugs": [
      "sacituzumab govitecan",
      "pembrolizumab",
      "chemotherapy"
    ],
    "biomarkers": [
      "PD-L1"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "660MO",
    "regimen": "regorafenib plus temozolomide with or without radiotherapy",
    "drugs": [
      "regorafenib",
      "temozolomide"
    ],
    "modality": [
      "TKI",
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "REGOM",
    "biomarkers": []
  },
  {
    "row_id": "1349P",
    "regimen": "Tipifarnib and alpelisib",
    "drugs": [
      "Tipifarnib",
      "alpelisib"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 1",
    "trial_id": "KURRENT-HN",
    "biomarkers": []
  },
  {
    "row_id": "LBA11",
    "regimen": "Neoadjuvant Toripalimab Plus Lenvatinib and GEMOX",
    "drugs": [
      "Toripalimab",
      "Lenvatinib",
      "GEMOX",
      "toripalimab"
    ],
    "modality": [
      "IO",
      "Chemotherapy",
      "Neoadjuvant"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase II-III",
    "trial_id": "",
    "biomarkers": []
  },
  {
    "row_id": "1399P",
    "regimen": "Prognostic model driven by explainable AI",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1399P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "663MO",
    "regimen": "IL13Ralpha2-targeted CAR-T cell therapy",
    "modality": [
      "CAR-T"
    ],
    "population": "Other",
    "phase": "Phase 1",
    "trial_id": "663MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1469MO",
    "regimen": "Liver resection versus continued atezolizumab plus bevacizumab",
    "drugs": [
      "atezolizumab",
      "bevacizumab"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1469MO",
    "biomarkers": []
  },
  {
    "row_id": "1851MO",
    "regimen": "Pembrolizumab plus chemotherapy",
    "drugs": [
      "pembrolizumab",
      "chemotherapy"
    ],
    "biomarkers": [
      "PD-L1"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "1851MO"
  },
  {
    "row_id": "485MO",
    "regimen": "Adding Palbociclib to HER2 and Endocrine Therapy",
    "drugs": [
      "Palbociclib",
      "HER2",
      "Endocrine Therapy"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "485MO",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "1336P",
    "regimen": "Definitive Radiotherapy Regimens",
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1336P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1459eP",
    "regimen": "Adjuvant Fluoropyrimidines Following Definitive Chemoradiotherapy",
    "drugs": [
      "Fluoropyrimidines"
    ],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "1459eP",
    "biomarkers": []
  },
  {
    "row_id": "1404P",
    "regimen": "Analysis Of Comorbidities And Demographic Factors",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1404P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1409P",
    "regimen": "NOTCH pathway in head and neck squamous cell carcinoma",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1409P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1443TiP",
    "regimen": "Pembrolizumab and Radiotherapy",
    "drugs": [
      "Pembrolizumab",
      "pembrolizumab"
    ],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 3",
    "trial_id": "EORTC 2014-HNCG PROLoNg",
    "biomarkers": []
  },
  {
    "row_id": "1395P",
    "regimen": "FID-007 Plus Cetuximab",
    "drugs": [
      "FID-007",
      "Cetuximab"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "R/M HNSCC",
    "biomarkers": []
  },
  {
    "row_id": "2214MO",
    "regimen": "telisotuzumab adizutecan",
    "drugs": [
      "telisotuzumab adizutecan"
    ],
    "modality": [
      "ADC"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "ABBV-400; Temab-A",
    "biomarkers": []
  },
  {
    "row_id": "1710MO",
    "regimen": "Belzutifan for Advanced Pancreatic Neuroendocrine Tumors",
    "drugs": [
      "Belzutifan"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "LITESPARK-015",
    "biomarkers": []
  },
  {
    "row_id": "1360P",
    "regimen": "Concurrent Weekly Carboplatin, Paclitaxel, and Cetuximab",
    "drugs": [
      "Carboplatin",
      "Paclitaxel",
      "Cetuximab",
      "carboplatin"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Not specified",
    "trial_id": "Recurrent or Metastatic Head and Neck Squamous Cell",
    "biomarkers": []
  },
  {
    "row_id": "1331P",
    "regimen": "induction chemotherapy with cisplatin, 5-fluorouracil and docetaxel",
    "drugs": [
      "cisplatin",
      "5-fluorouracil",
      "docetaxel"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "GORTEC 2019-01",
    "biomarkers": []
  },
  {
    "row_id": "1440TiP",
    "regimen": "Tislelizumab Plus Gemcitabine/Capecitabine versus Tislelizumab Plus Gemcitabine/Cisplatin",
    "drugs": [
      "Tislelizumab",
      "Gemcitabine",
      "Capecitabine",
      "Cisplatin",
      "tislelizumab",
      "gemcitabine",
      "cisplatin"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 3",
    "trial_id": "Recurrent/Metastatic Nasopharyngeal",
    "biomarkers": []
  },
  {
    "row_id": "1375P",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1375P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1334P",
    "regimen": "neoadjuvant pembrolizumab combined with low-dose cisplatin and 5-fluorouracil",
    "drugs": [
      "pembrolizumab",
      "cisplatin",
      "5-fluorouracil"
    ],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "1334P",
    "biomarkers": []
  },
  {
    "row_id": "1342P",
    "regimen": "neoadjuvant anti-PD1 with low-dose cisplatin/5-fluorouracil",
    "drugs": [
      "anti-PD1",
      "cisplatin",
      "5-fluorouracil"
    ],
    "modality": [
      "IO",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "1342P",
    "biomarkers": []
  },
  {
    "row_id": "1451eP",
    "regimen": "neoadjuvant chemoimmunotherapy",
    "modality": [
      "Chemotherapy",
      "IO"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "1451eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1321O",
    "regimen": "Concurrent Chemoradiotherapy with/without Adjuvant Capecitabine",
    "drugs": [
      "Capecitabine"
    ],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Phase 3",
    "trial_id": "1321O",
    "biomarkers": []
  },
  {
    "row_id": "1413P",
    "regimen": "Cisplatin Chemoresistance via the EGFR-JAK2-STAT3 Pathway",
    "drugs": [
      "Cisplatin",
      "cisplatin"
    ],
    "biomarkers": [
      "DDAH1",
      "EGFR",
      "JAK2",
      "STAT3"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1413P"
  },
  {
    "row_id": "1453eP",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1453eP",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1434P",
    "regimen": "High-Dose Cisplatin Chemoradiotherapy",
    "drugs": [
      "Cisplatin",
      "cisplatin"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1434P",
    "biomarkers": []
  },
  {
    "row_id": "LBA70",
    "regimen": "association of radiomic features +/- on-treatment ctDNA detection",
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "LBA70",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1034MO",
    "regimen": "Targeted Alpha Therapy",
    "drugs": [
      "Targeted Alpha Therapy"
    ],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1034MO",
    "biomarkers": []
  },
  {
    "row_id": "1365P",
    "regimen": "risk-adapted phase 2 study",
    "drugs": [
      "HPV circulating tumor DNA"
    ],
    "population": "Other",
    "phase": "Phase 2",
    "trial_id": "1365P",
    "biomarkers": []
  },
  {
    "row_id": "1414P",
    "regimen": "Next Generation Sequencing (NGS) Analysis",
    "drugs": [
      "Next Generation Sequencing"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1414P",
    "biomarkers": []
  },
  {
    "row_id": "1384P",
    "regimen": "Photoimmunotherapy",
    "drugs": [
      "Photoimmunotherapy"
    ],
    "modality": [
      "IO"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1384P",
    "biomarkers": []
  },
  {
    "row_id": "1397P",
    "regimen": "personalized drug therapy selection",
    "drugs": [
      "patient-derived organoids"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1397P",
    "biomarkers": []
  },
  {
    "row_id": "457eP",
    "regimen": "neoadjuvant chemotherapy",
    "drugs": [
      "chemotherapy"
    ],
    "modality": [
      "Neoadjuvant"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "457eP",
    "biomarkers": []
  },
  {
    "row_id": "1442TiP",
    "regimen": "Peri-radiotherapy immunotherapy",
    "drugs": [
      "immunotherapy"
    ],
    "modality": [
      "IO",
      "Radiotherapy"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1442TiP",
    "biomarkers": []
  },
  {
    "row_id": "270eP",
    "regimen": "Peritumoral desmoplasia",
    "drugs": [],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "270eP",
    "biomarkers": []
  },
  {
    "row_id": "1422P",
    "regimen": "PD-1 inhibitor or cetuximab combined with chemotherapy",
    "drugs": [
      "PD-1 inhibitor",
      "cetuximab",
      "chemotherapy"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "1422P",
    "biomarkers": []
  },
  {
    "row_id": "1457eP",
    "regimen": "TPF regimen chrono-chemotherapy combined with cisplatin concurrent chemoradiotherapy",
    "drugs": [
      "TPF regimen",
      "cisplatin",
      "chemoradiotherapy"
    ],
    "modality": [
      "Chemotherapy",
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "1457eP",
    "biomarkers": []
  },
  {
    "row_id": "664MO",
    "regimen": "larotrectinib",
    "drugs": [
      "larotrectinib"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "664MO",
    "biomarkers": []
  },
  {
    "row_id": "504P",
    "regimen": "First-Line (1L) treatment in HR+ HER2- Metastatic Breast Cancer",
    "drugs": [
      "ESR1 mutations",
      "AKT Pathway"
    ],
    "biomarkers": [
      "ESR1m",
      "AKTp",
      "HER2"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "504P"
  },
  {
    "row_id": "1035MO",
    "regimen": "Prediction Tool for Malnutrition and Sarcopenia",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "GETNE-S2109"
  },
  {
    "row_id": "489MO",
    "regimen": "vepdegestrant vs fulvestrant",
    "drugs": [
      "vepdegestrant",
      "fulvestrant"
    ],
    "biomarkers": [
      "ESR1m",
      "HER2"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1460eP",
    "regimen": "Personalized Targeted Therapies",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1340P",
    "regimen": "GM-CSF on prevention and treatment of oral mucositis",
    "drugs": [
      "GM-CSF"
    ],
    "biomarkers": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "ChiCTR2300068457"
  },
  {
    "row_id": "1417P",
    "regimen": "immunonutrition on oral mucositis",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "479P",
    "regimen": "H4K8la/CXCL10-driven M2 polarization",
    "drugs": [
      "doxorubicin"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": ""
  },
  {
    "row_id": "1354P",
    "regimen": "discontinuation of immune checkpoint inhibitors",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "1354P"
  },
  {
    "row_id": "1350P",
    "regimen": "Immuno-Chemotherapy Alone",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "2L",
    "phase": "Phase 2",
    "trial_id": "1350P"
  },
  {
    "row_id": "2216MO",
    "regimen": "Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01",
    "drugs": [
      "Nab-Paclitaxel",
      "Gemcitabine",
      "VCN-01",
      "gemcitabine"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Phase 2b",
    "trial_id": "2216MO"
  },
  {
    "row_id": "1429P",
    "regimen": "cytotoxic chemotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "1429P"
  },
  {
    "row_id": "1427P",
    "regimen": "photoimmunotherapy",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "1427P"
  },
  {
    "row_id": "1411P",
    "regimen": "PD-1 inhibitors",
    "drugs": [],
    "biomarkers": [
      "PD-1"
    ],
    "modality": [],
    "population": "Other",
    "line": "Other",
    "phase": "Not specified",
    "trial_id": "1411P"
  },
  {
    "row_id": "1344P",
    "regimen": "neoadjuvant immunochemotherapy and radical surgery",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "1344P"
  },
  {
    "row_id": "ROW_4310",
    "trial_id": "ROW_4310",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1380P",
    "regimen": "metronomic capecitabine adjuvant chemotherapy",
    "drugs": [
      "capecitabine"
    ],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "1380P",
    "biomarkers": []
  },
  {
    "row_id": "1333P",
    "regimen": "adjuvant radiotherapy",
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "1333P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1433P",
    "trial_id": "1433P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1364P",
    "trial_id": "1364P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "ROW_4330",
    "trial_id": "ROW_4330",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "2281MO",
    "trial_id": "2281MO",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1407P",
    "trial_id": "1407P",
    "drugs": [],
    "biomarkers": []
  },
  {
    "row_id": "1441TiP",
    "regimen": "SIRPalpha monoclonal antibody BI 770371 in combination with pembrolizumab",
    "drugs": [
      "BI 770371",
      "pembrolizumab",
      "cetuximab"
    ],
    "phase": "Phase Ib",
    "trial_id": "1441TiP",
    "biomarkers": []
  },
  {
    "row_id": "1708MO",
    "regimen": "ZG005 in combination with etoposide and cisplatin",
    "drugs": [
      "ZG005",
      "etoposide",
      "cisplatin"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Not specified",
    "trial_id": "1708MO",
    "biomarkers": []
  },
  {
    "row_id": "1343P",
    "regimen": "Neoadjuvant Tislelizumab Plus Chemotherapy",
    "drugs": [
      "Tislelizumab",
      "tislelizumab"
    ],
    "modality": [
      "Chemotherapy",
      "Neoadjuvant"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "NeoSPOT",
    "biomarkers": []
  },
  {
    "row_id": "536MO",
    "regimen": "SHR-A1811 plus pertuzumab",
    "drugs": [
      "SHR-A1811",
      "pertuzumab"
    ],
    "modality": [
      "TKI"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 1",
    "trial_id": "Not specified",
    "biomarkers": [
      "HER2"
    ]
  },
  {
    "row_id": "1347P",
    "regimen": "Neoadjuvant PD-1 Inhibitor Combined with Chemotherapy",
    "drugs": [
      "PD-1 Inhibitor"
    ],
    "modality": [
      "Chemotherapy",
      "Neoadjuvant"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "1378P",
    "regimen": "Envafolimab plus chemoradiotherapy",
    "drugs": [
      "Envafolimab"
    ],
    "modality": [
      "Chemotherapy",
      "Radiotherapy",
      "Neoadjuvant"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Phase 2",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "1358P",
    "regimen": "Combination of Cadonilimab and Low-Dose Radiotherapy",
    "drugs": [
      "Cadonilimab"
    ],
    "modality": [
      "Radiotherapy"
    ],
    "population": "Other",
    "line": "Not specified",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "1335P",
    "regimen": "Neoadjuvant Tislelizumab Plus Platinum-Based Doublet Chemotherapy",
    "drugs": [
      "Tislelizumab",
      "tislelizumab"
    ],
    "modality": [
      "Chemotherapy",
      "Neoadjuvant"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "Not specified",
    "biomarkers": []
  },
  {
    "row_id": "1376P",
    "regimen": "Immune Checkpoint Inhibitors",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1376P"
  },
  {
    "row_id": "665MO",
    "regimen": "DNA methylation-based epigenetic signatures",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "665MO"
  },
  {
    "row_id": "652eTiP",
    "regimen": "FWD1802 with CDK4/6 inhibitors and mTOR inhibitor",
    "drugs": [
      "FWD1802",
      "CDK4/6 inhibitors",
      "mTOR inhibitor"
    ],
    "biomarkers": [
      "ER",
      "HER2"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Phase 1",
    "trial_id": "652eTiP"
  },
  {
    "row_id": "1339P",
    "regimen": "Neoadjuvant Chemotherapy Plus Toripalimab",
    "drugs": [
      "Toripalimab",
      "toripalimab"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "1339P"
  },
  {
    "row_id": "11P",
    "regimen": "KAT5-mediated immunotherapy resistance interventions",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "11P"
  },
  {
    "row_id": "1332P",
    "regimen": "SBRT followed by neoadjuvant chemo-immunotherapy of Sintilimab plus docetaxel and cisplatin",
    "drugs": [
      "Sintilimab",
      "docetaxel",
      "cisplatin"
    ],
    "biomarkers": [],
    "modality": [
      "Radiotherapy",
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "1332P"
  },
  {
    "row_id": "1383P",
    "regimen": "Cetuximab-Enhanced Induction Chemotherapy",
    "drugs": [
      "Cetuximab"
    ],
    "biomarkers": [],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1383P"
  },
  {
    "row_id": "1355P",
    "regimen": "docetaxel plus pembrolizumab combination treatment",
    "drugs": [
      "docetaxel",
      "pembrolizumab"
    ],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Phase 2",
    "trial_id": "1355P"
  },
  {
    "row_id": "1456eP",
    "regimen": "Gunagratinib in patients with head and neck cancer",
    "drugs": [
      "Gunagratinib"
    ],
    "biomarkers": [
      "FGFR"
    ],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1456eP"
  },
  {
    "row_id": "1386P",
    "regimen": "Deep Learning-Based Time-Habitat Longitudinal MRI Radiomics Model",
    "drugs": [],
    "biomarkers": [],
    "modality": [],
    "population": "Other",
    "line": "",
    "phase": "Not specified",
    "trial_id": "1386P"
  },
  {
    "row_id": "1454eP",
    "regimen": "Benmelstobart Combined with Anlotinib and Chemotherapy",
    "drugs": [
      "Benmelstobart",
      "Anlotinib"
    ],
    "modality": [
      "Chemotherapy"
    ],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Phase 2",
    "trial_id": "1454eP",
    "biomarkers": []
  },
  {
    "row_id": "1382P",
    "regimen": "Next-generation sequencing detection of Epstein-Barr virus and microbiome signatures",
    "drugs": [],
    "biomarkers": [
      "Epstein-Barr virus"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1382P"
  },
  {
    "row_id": "1396P",
    "regimen": "Circulating tumor DNA for Minimal Disease Detection",
    "drugs": [],
    "biomarkers": [
      "ctDNA"
    ],
    "population": "Other",
    "phase": "Not specified",
    "trial_id": "1396P"
  },
  {
    "row_id": "1423P",
    "regimen": "Neoadjuvant Immunotherapy",
    "drugs": [],
    "population": "Other",
    "line": "Neoadjuvant",
    "phase": "Not specified",
    "trial_id": "1423P",
    "biomarkers": []
  },
  {
    "row_id": "1389P",
    "regimen": "Becotatug Vedotin in combination with Pucotenlimab",
    "drugs": [
      "Becotatug Vedotin",
      "Pucotenlimab"
    ],
    "population": "Other",
    "line": "1L",
    "phase": "Phase 2",
    "trial_id": "1389P",
    "biomarkers": []
  },
  {
    "row_id": "1381P",
    "regimen": "Adjuvant treatment for metastatic nasopharyngeal carcinoma",
    "drugs": [],
    "population": "Other",
    "line": "Adjuvant",
    "phase": "Not specified",
    "trial_id": "1381P",
    "biomarkers": []
  },
  {
    "row_id": "ROW_4665",
    "population": "Other",
    "trial_id": "ROW_4665",
    "drugs": [],
    "biomarkers": []
  }
]